Industry News (Joint Venture)

Collaboration Entered To Develop Gelatinase Inhibitors

Published in Cancer Weekly, October 23rd, 1995

Celltech, Slough, United Kingdom (U.K.), announced it has entered into a collaboration with Zeneca to develop gelatinase inhibitors for use in cancer therapy.

The collaboration will provide up to ten million pounds sterling ($15.8 million) in milestone payments to Celltech, subject to satisfactory clinical progress, which will in addition receive royalties on worldwide sales of products that arise from the collaboration.

The ability of tumors to grow and spread in the body depends upon their capacity to form new blood vessels and to digest surrounding tissues. Gelatinase, a member of the matrix metalloproteinase class of enzymes, has been implicated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry